Literature DB >> 29796096

Impact of Clostridium difficile toxin gene PCR result on decisions to de-isolate patients: Do the ends justify the means?

Kirsti A Morris1, Kerrie Davies1,2, Mark H Wilcox1,2.   

Abstract

We aimed to determine how often Clostridium difficile toxin gene PCR assay (CDPCR)-negative patients were appropriately removed from single room contact isolation. Hospital databases were used to collect information on glutamate dehydrogenase (GDH)-positive, toxin-negative inpatients (February-April 2015). Of 60 CDPCR-negative patients, only two (3%) were removed from single room isolation. At least 36% of 53 CDPCR-positive results did not influence bed management. In conclusion, identification of C. difficile toxigenic status did not impact significantly on decisions whether to continue single room isolation. Cost-benefit analysis should be undertaken before CDPCR testing is introduced.

Entities:  

Keywords:  Clostridium difficile; PCR; single room; toxigenic status

Year:  2018        PMID: 29796096      PMCID: PMC5956705          DOI: 10.1177/1757177418755309

Source DB:  PubMed          Journal:  J Infect Prev        ISSN: 1757-1782


  3 in total

Review 1.  Clostridium difficile infection: clinical challenges and management strategies.

Authors:  Pamela R Walters; Brian S Zuckerbraun
Journal:  Crit Care Nurse       Date:  2014-08       Impact factor: 1.708

2.  European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection.

Authors:  M J T Crobach; T Planche; C Eckert; F Barbut; E M Terveer; O M Dekkers; M H Wilcox; E J Kuijper
Journal:  Clin Microbiol Infect       Date:  2016-07-25       Impact factor: 8.067

3.  Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection.

Authors:  Timothy D Planche; Kerrie A Davies; Pietro G Coen; John M Finney; Irene M Monahan; Kirsti A Morris; Lily O'Connor; Sarah J Oakley; Cassie F Pope; Mike W Wren; Nandini P Shetty; Derrick W Crook; Mark H Wilcox
Journal:  Lancet Infect Dis       Date:  2013-09-03       Impact factor: 25.071

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.